Aprea Therapeutics Inc (APRE)

Mar 12, 2026

Plus: Q4 Earnings Snapshot - Barchart.com

Mar 12, 2026

Mar 09, 2026

Aprea Therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial - MSN

Mar 09, 2026

Mar 07, 2026

Published on: 2026-03-07 13:05:37 - baoquankhu1.vn

Mar 07, 2026

Mar 05, 2026

Stock Report: Is Aprea Therapeutics Inc backed by strong institutional buyingJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn

Mar 05, 2026

Mar 04, 2026

Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart.com

Mar 04, 2026

Feb 26, 2026

APRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 26, 2026

Feb 24, 2026

Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial - MyChesCo

Feb 24, 2026

Feb 23, 2026

Aprea to Present at Oppenheimer Healthcare Conference - MyChesCo

Feb 23, 2026

Feb 20, 2026

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits

Feb 20, 2026

Feb 20, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Feb 20, 2026

Feb 19, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Feb 19, 2026

Feb 19, 2026

Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research - Defense World

Feb 19, 2026

Feb 18, 2026

Aprea reports second partial response in endometrial cancer trial - Investing.com South Africa

Feb 18, 2026

Feb 18, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Feb 18, 2026

Feb 18, 2026

Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga

Feb 18, 2026

Feb 18, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Feb 18, 2026

Feb 18, 2026

Aprea Therapeutics announces additional positive clinical activity for Wee1 inhibitor, APR-1051 - marketscreener.com

Feb 18, 2026

Feb 18, 2026

Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051 - TradingView

Feb 18, 2026

Feb 18, 2026

Aprea Highlights Encouraging Phase 1 Data for APR-1051 - TipRanks

Feb 18, 2026

Feb 18, 2026

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - The Manila Times

Feb 18, 2026

Feb 18, 2026

Experimental cancer drug shrinks endometrial tumor by 50% in early trial - Stock Titan

Feb 18, 2026

Feb 17, 2026

Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - VISTA.Today

Feb 17, 2026

Feb 17, 2026

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget

Feb 17, 2026

Feb 15, 2026

IPO Launch: Is Aprea Therapeutics Inc gaining market shareWeekly Market Summary & Daily Profit Maximizing Tips - baoquankhu1.vn

Feb 15, 2026

Feb 15, 2026

Will Aprea Therapeutics Inc. stock hit new highs in YEARQuarterly Trade Summary & Weekly High Return Forecasts - mfd.ru

Feb 15, 2026

Feb 13, 2026

Is Aprea Therapeutics Inc. a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - mfd.ru

Feb 13, 2026

Feb 13, 2026

Will Aprea Therapeutics Inc. stock go up in YEARJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru

Feb 13, 2026

Feb 13, 2026

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growthboerse.de - boerse.de

Feb 13, 2026

Feb 12, 2026

Aprea taps veteran oncologist as clinical momentum builds for lead cancer drug - MSN

Feb 12, 2026

Feb 12, 2026

Aprea Therapeutics strengthens global patent portfolio in DNA Damage Response (DDR) cancer therapeutics - marketscreener.com

Feb 12, 2026

Feb 12, 2026

Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics - TradingView

Feb 12, 2026

Feb 12, 2026

Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative

Feb 12, 2026

Feb 12, 2026

Cancer therapy company Aprea wins patents guarding new treatments into 2045 - Stock Titan

Feb 12, 2026

Feb 10, 2026

What hedge funds are buying Aprea Therapeutics Inc.Quarterly Profit Summary & Growth Focused Stock Reports - mfd.ru

Feb 10, 2026

Feb 10, 2026

Aprea Therapeutics (APRE): Analyst Maintains Rating, Lowers Pric - GuruFocus

Feb 10, 2026

Feb 08, 2026

Aprea Taps Veteran Oncologist as Clinical Momentum Builds for Lead Cancer Drug - MyChesCo

Feb 08, 2026

Feb 07, 2026

Early cancer signal emerges as Aprea drug shrinks tumors in phase 1 trial - MSN

Feb 07, 2026

Feb 04, 2026

Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor By Investing.com - Investing.com Nigeria

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics Appoints Eugene Kennedy, MD, as Chief Medical Advisor - citybiz

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics appoints Eugene Kennedy as chief medical advisor - Investing.com

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics Appoints New Chief Medical Advisor - Intellectia AI

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics Appoints Dr. Eugene Kennedy as Chief Medical Advisor to Enhance Oncology Program Development - Quiver Quantitative

Feb 04, 2026

Feb 04, 2026

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - The Manila Times

Feb 04, 2026

Feb 03, 2026

Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial - MyChesCo

Feb 03, 2026

Feb 03, 2026

Aprea Therapeutics (APRE) CEO buys $25,000 in shares By Investing.com - Investing.com India

Feb 03, 2026